Contrasting of NantKwest Inc. (NK) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)

As Biotechnology businesses, NantKwest Inc. (NASDAQ:NK) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), are affected by contrast. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NantKwest Inc. N/A 2141.44 86.59M -1.22 0.00
Intercept Pharmaceuticals Inc. 196.09M 13.25 317.92M -10.75 0.00

Table 1 demonstrates NantKwest Inc. and Intercept Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of NantKwest Inc. and Intercept Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
NantKwest Inc. 0.00% -52.7% -43.1%
Intercept Pharmaceuticals Inc. -162.13% -615.8% -60.3%

Volatility & Risk

A 2.5 beta indicates that NantKwest Inc. is 150.00% more volatile compared to Standard and Poor’s 500. Intercept Pharmaceuticals Inc.’s 51.00% more volatile than Standard and Poor’s 500 which is a result of the 1.51 beta.

Liquidity

NantKwest Inc. has a Current Ratio of 4.1 and a Quick Ratio of 4.1. Competitively, Intercept Pharmaceuticals Inc.’s Current Ratio is 3.7 and has 3.7 Quick Ratio. NantKwest Inc.’s better ability to pay short and long-term obligations than Intercept Pharmaceuticals Inc.

Analyst Recommendations

In next table is given NantKwest Inc. and Intercept Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NantKwest Inc. 0 0 0 0.00
Intercept Pharmaceuticals Inc. 1 3 11 2.73

$1.25 is NantKwest Inc.’s average target price while its potential upside is 22.55%. Intercept Pharmaceuticals Inc. on the other hand boasts of a $163.69 average target price and a 105.85% potential upside. The information presented earlier suggests that Intercept Pharmaceuticals Inc. looks more robust than NantKwest Inc. as far as analyst view.

Insider & Institutional Ownership

Roughly 8.9% of NantKwest Inc. shares are owned by institutional investors while 70.8% of Intercept Pharmaceuticals Inc. are owned by institutional investors. About 20.3% of NantKwest Inc.’s share are owned by insiders. Comparatively, insiders own roughly 22.9% of Intercept Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NantKwest Inc. -4.27% -23.29% 0% -59.27% -73.4% -3.45%
Intercept Pharmaceuticals Inc. 0.79% -4.33% -20.02% -18.89% 23.1% -12.43%

For the past year NantKwest Inc. has stronger performance than Intercept Pharmaceuticals Inc.

Summary

NantKwest Inc. beats Intercept Pharmaceuticals Inc. on 8 of the 11 factors.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.